Dynavax to Announce Q2 2024 Financials and Host Call on August 6, 2024

EMERYVILLE, Calif., July 23, 2024 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing innovative vaccines, will announce its second-quarter 2024 financial results on Tuesday, August 6, 2024, following the closure of U.S. financial markets.

A conference call and live audio webcast will be hosted by Dynavax on the same day at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast can be accessed via the "Events & Presentations" section under the "Investors" tab on the Company's website. The webcast will be available for replay for 30 days after the live event.

Participants wishing to join the call must register through the provided caller registration link. It is recommended to connect to the conference call or log into the webcast about 10 minutes early.

Dynavax is a commercial-stage biopharmaceutical firm dedicated to the development and commercialization of innovative vaccines aimed at protecting against infectious diseases. The Company markets two products: HEPLISAV-B® vaccine and CpG 1018® adjuvant. HEPLISAV-B®, a Hepatitis B Vaccine (Recombinant), Adjuvanted, is approved in the United States, the European Union, and Great Britain for preventing infections caused by all known hepatitis B virus subtypes in adults aged 18 and older. CpG 1018® adjuvant is incorporated in several adjuvanted COVID-19 vaccines.

The Company is promoting CpG 1018 adjuvant as a leading vaccine adjuvant, with clinical programs underway for vaccines against shingles and Tdap. Dynavax is also engaging in global collaborations to develop adjuvanted vaccines targeting COVID-19, plague, seasonal influenza, and universal influenza. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!